Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma

Summary

The purpose of this study is to look at the efficacy and safety of sintilimab in combination with carboplatin and nab-paclitaxel in patients with oral cavity or oropharyngeal squamous cell carcinoma who are about to undergo surgery. Monoclonal antibodies, such as sintilimab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving sintilimab, carboplatin, and nab-paclitaxel may work better in treating patients with oral cavity and oropharyngeal squamous cell carcinoma.

Timeline

Start

2021-01-23

Primary completion

2023-01-01

Completion

2027-01-23

Publications

• Liu N, Wu J, Deng E, Zhong J, Wei B, Cai T, Xie Z, Duan X, Fu S, Osei-Hwedieh DO, Huang K, Zhuang P, Sha O, Chen Y, Lv X, Zhu Y, Zhang L, Lin H, Li Q, Lu P, Miao J, Yamada T, Cai L, Du H, Baca SC, Huang Q, Ferrone S, Wang X, Xu F, Fan X, Fan S. Immunotherapy and senolytics in head and neck squamous cell carcinoma: phase 2 trial results. Nat Med. 2025 Sep;31(9):3047-3061. doi: 10.1038/s41591-025-03873-7. Epub 2025 Aug 25.

Drugs

Indications